Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. - Wikidata - awgldk - TriplyDB

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.

http://www.wikidata.org/entity/Q35172203

about

The mTOR signalling pathway in human cancer The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy Differentiating mTOR inhibitors in renal cell carcinoma Old drug, new trick: repurposing metformin for gynecologic cancers?Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.Chemoresistance and targeted therapies in ovarian and endometrial cancers What Is the Best Preoperative Imaging for Endometrial Cancer?Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.Current phase II clinical data for ridaforolimus in cancer.Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT.Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.The IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting Approaches SHARP1 suppresses angiogenesis of endometrial cancer by decreasing hypoxia-inducible factor-1α level Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma Suppression of the epithelial-mesenchymal transition by SHARP1 is linked to the NOTCH1 signaling pathway in metastasis of endometrial cancer Fulvestrant for the treatment of endometrial cancer.Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.The role of Hypoxia-inducible factor-1 α , glucose transporter-1, (GLUT-1) and carbon anhydrase IX in endometrial cancer patients Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma.Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.Personalized therapy in endometrial cancer: challenges and opportunities.Lipocalin 2 Enhances Migration and Resistance against Cisplatin in Endometrial Carcinoma Cells.PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.The genomics and genetics of endometrial cancer.A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.Major clinical research advances in gynecologic cancer in 2012.Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis.Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.Phase II trial of temsirolimus in patients with metastatic breast cancer.Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.Clinical prognostic significance and pro-metastatic activity of RANK/RANKL via the AKT pathway in endometrial cancer

P2860

Q24627306-FA0605D9-8F4D-452A-B7E8-05E628EA4348 Q26744087-96FD9960-E619-49F2-AED4-CC7B26EC7B18 Q26860172-35BE2799-7577-4081-BD5B-879A6ACB16F3 Q27010558-F140383F-4FDA-4689-8AF2-2DC3D7E84958 Q27851999-B4037FFA-63EE-4EE7-A5F4-1F975671426B Q27852528-8BE1258B-3184-4A3C-8402-B4633A8A5405 Q27852608-8057058B-741D-484C-8CC7-4CB770A305BC Q28073246-2CC6EF62-BE20-484C-A3E2-722C59E9BA82 Q28077761-D53520F3-6800-4C0B-A425-F62B78652614 Q30407709-3C112936-8CBA-423A-ABE4-B07763EF1C68 Q30662689-3A5BB9B8-C3E4-485B-AFF5-E04681CD010A Q33413585-87DB5F58-E663-4067-8E36-8CB61BAE05C7 Q33414685-DEE79828-0648-4213-B269-10CE6B83933C Q33422258-8E1845A9-80AD-46C7-B078-61AD170357EE Q33442539-55046B86-5E54-4411-A91C-DA1E3CD2728C Q33658023-DED8DA99-1CB2-4FEA-8914-9CC660441F87 Q33740510-61C20A9F-B5AF-4C54-9D59-C2BEF46AF752 Q34272887-6C21C11A-0640-48C2-82C9-DA31B06822CA Q34291001-FDEF7DB1-48FC-42E8-B8C5-2B641371EEBB Q34393036-00259FCC-B1D6-49CD-8755-A1C59526984C Q34485913-71221C2B-9572-4A91-A7C8-5719C63F45F2 Q34514391-5C41EF87-7B20-4334-9880-E042E05D4723 Q34571141-7DA17574-5574-408A-B832-128F01582D19 Q34781699-63A50625-62E1-4C3F-8A19-1E4E0DBBE019 Q35152277-8BBEBC68-64A0-4DB7-949A-FD9E12420709 Q35740059-2F15F5B8-6DDA-4BD1-BDC4-882059DFB778 Q35879733-7A694D3C-EA7D-40F7-B54F-4DD340BCD71A Q35911350-6C854E52-06F0-430F-A0B3-D8E74083CDCD Q36014604-3BDAFE58-00BA-4945-A117-01CA1C5DCD82 Q36096004-0043EFDD-AB50-4D7E-B2D3-CBEFA4C7AB5E Q36151896-57ACA31B-9D57-4D5E-8C29-1057A5CA4E03 Q36274386-81E96485-B63E-4BE3-9610-5C78AE93E940 Q36418630-5136AA5D-85EE-42BB-BF7C-0C3BC899D94B Q36547047-71354560-231A-408E-93FC-865AE5D62B98 Q36553511-628AA739-CBC7-4506-8102-E7998C5521E1 Q36731185-7F847E8D-430D-4C94-8B0C-051173438EC1 Q36746785-8BEE729D-08C0-445D-A3E9-9DE8556DC2D5 Q36856121-7A98A223-0E40-46E4-9071-523C2E4B00B9 Q36857470-96DBB421-C8F2-4B85-BFB7-932A53AD60C1 Q36905719-7564B331-F0AB-4EE3-AD41-115995B235A4

P2860

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.

http://www.wikidata.org/entity/Q35172203

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phase II study of temsirolimus ...... he NCIC Clinical Trials Group.

@ast

Phase II study of temsirolimus ...... he NCIC Clinical Trials Group.

@en

type

label

Phase II study of temsirolimus ...... he NCIC Clinical Trials Group.

@ast

Phase II study of temsirolimus ...... he NCIC Clinical Trials Group.

@en

prefLabel

Phase II study of temsirolimus ...... he NCIC Clinical Trials Group.

@ast

Phase II study of temsirolimus ...... he NCIC Clinical Trials Group.

@en

P1433

Q35172203-A17845B8-63CA-4B55-8CD1-23AB0A770F38

P1476

Q35172203-04E534D7-0D2F-4C96-99D0-7547E9144C8F

P2093

Q35172203-0912A69E-8EC8-4D69-942C-44622B40235C

Q35172203-112F2B48-2ECC-412A-B93D-EC3986833B1B

Q35172203-28B58767-05B6-4222-B3F3-8A90F50F6D88

Q35172203-42813CC7-7157-4878-B13A-BC729A09080C

Q35172203-4D2EA8EE-7DC7-4D69-A180-AA4DA5CEE832

Q35172203-501409D6-A098-4F73-B0DD-625F565675FB

Q35172203-6F6A1278-44DC-4121-BE20-D6D749AD5754

Q35172203-7A56357E-4C6C-45F4-896A-41887D236D68

Q35172203-A9EB5F2C-9792-4A37-92B2-5BBDC4112EF9

Q35172203-C4293E79-FF08-45E8-8A85-A66602160BC6

P2860

Q35172203-052A6EC3-F8A0-4775-BE86-6810A669FADE

Q35172203-0D0EDCD9-309A-48EB-8AB9-E6DC1B7DC21F

Q35172203-177DCBA0-19D1-4C14-A69B-DE124979210A

Q35172203-23719A3B-82C9-4FA3-9147-F85EB3976D9C

Q35172203-2E056B34-E168-4505-B6B2-811043AB71FB

Q35172203-2EB7CAFA-3FF6-402C-B29F-24AD9154EFCC

Q35172203-3A76FC47-3877-4859-847D-FDA0E64BF97B

Q35172203-3E2FD2A6-7462-489A-8C84-E24617E239C3

Q35172203-426FD22C-5C73-4D55-9FB4-61B398B0ABB6

Q35172203-42E92C8D-CA18-440E-B5F0-037996EF1387

P304

Q35172203-AD34F84F-085C-427B-A867-0653D698348B

P31

Q35172203-D40EB641-AB23-4BFC-AD4D-5AEDBF51A77F

P356

Q35172203-A4F1BD32-E36C-4177-9FA4-0BB3E1828835

P407

Q35172203-44AB0A63-D917-400E-9D08-0802A5500899

P433

Q35172203-C2F45691-0256-4BAB-AC40-CCDAB9EA8CA5

P478

Q35172203-1B0DF43C-755D-45EA-9548-66EC77DA2062

P50

Q35172203-9F422554-3BE2-47A0-B2A2-CFEC880AD98E

Q35172203-E45727D2-84EF-47D3-B1DB-7948FC53F81F

P577

Q35172203-FCACBFF2-2631-47E3-8823-27CDE2223537

P698

Q35172203-FAC22103-6D31-4CC1-B613-08609B0E3127

P921

Q35172203-04A76354-74BF-4BF1-9098-D845FF4D6906

P932

Q35172203-7EF85A17-84E4-4F98-BD0D-FEEC9A181F3C

P356

JCO.2010.34.1578

P1433

Journal of Clinical Oncology

P1476

Phase II study of temsirolimus ...... he NCIC Clinical Trials Group.

@en

P2093

Amit M Oza

http://www.w3.org/2001/XMLSchema#string

Diane Michele Provencher

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Eisenhauer

http://www.w3.org/2001/XMLSchema#string

Helen J Mackay

http://www.w3.org/2001/XMLSchema#string

Janet E Dancey

http://www.w3.org/2001/XMLSchema#string

Jim Biagi

http://www.w3.org/2001/XMLSchema#string

Joana Sederias

http://www.w3.org/2001/XMLSchema#string

John Mazurka

http://www.w3.org/2001/XMLSchema#string

Katia S Tonkin

http://www.w3.org/2001/XMLSchema#string

Laurie Elit

http://www.w3.org/2001/XMLSchema#string

P2860

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Cancer statistics, 2009

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.

A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report.

AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma.

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.

A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.

P304

3278-3285

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.34.1578

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Suzanne Kamel-Reid

Ming-Sound Tsao

P577

2011-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21788564

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3158598

http://www.w3.org/2001/XMLSchema#string